Biomarkers must be both easy to detect and measure if they are to be used clinically. In addition, the use of a panel of biomarkers as opposed to a single biomarker can offer more robust and accurate results while minimizing the risk of false positives.
As such, circulating autoantibodies represent a pertinent source of early diagnostic and presymptomatic biomarkers for a number of pathologies including certain cancers and autoimmune diseases.
OGT has experience in the development of such panels using a number of different technologies. Core to the autoantibody area is Sense Proteomic’s functional protein array technology. This uses a BCCP fusion tag to provide the assurance that immobilized proteins are properly folded and hence native conformational epitopes are presented on the surface of each protein. As a result, the diagnostic autoantibody biomarker panels developed form sensitive and highly selective pathology fingerprints.